SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 208 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $102,000 | -62.2% | 11,300 | -50.0% | 0.00% | – |
| Q2 2021 | $270,000 | +365.5% | 22,600 | +391.3% | 0.00% | – |
| Q1 2021 | $58,000 | -85.3% | 4,600 | 0.0% | 0.00% | – |
| Q4 2020 | $395,000 | +797.7% | 4,600 | 0.0% | 0.00% | – |
| Q3 2020 | $44,000 | +4.8% | 4,600 | 0.0% | 0.00% | – |
| Q2 2020 | $42,000 | +180.0% | 4,600 | +100.0% | 0.00% | – |
| Q1 2020 | $15,000 | -21.1% | 2,300 | 0.0% | 0.00% | – |
| Q4 2019 | $19,000 | +850.0% | 2,300 | +1252.9% | 0.00% | – |
| Q3 2019 | $2,000 | -85.7% | 170 | -86.9% | 0.00% | – |
| Q2 2019 | $14,000 | +16.7% | 1,300 | 0.0% | 0.00% | – |
| Q1 2019 | $12,000 | +20.0% | 1,300 | +52.9% | 0.00% | – |
| Q4 2018 | $10,000 | -28.6% | 850 | 0.0% | 0.00% | – |
| Q3 2018 | $14,000 | +16.7% | 850 | 0.0% | 0.00% | – |
| Q2 2018 | $12,000 | +33.3% | 850 | +88.9% | 0.00% | – |
| Q1 2018 | $9,000 | +28.6% | 450 | 0.0% | 0.00% | – |
| Q4 2017 | $7,000 | – | 450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |